# BATCH2-PROMOTE-1-CONTINUATION — Runtime Activation STOP-Gated Completion

**Work ID:** `BATCH2-PROMOTE-1-CONTINUATION_runtime_activation_stop_gated_completion`  
**Date:** 2026-06-06  
**SOP:** AUTOMATION_BUS_SOP_v1.3.1

---

## Executive verdict

**STOP GATE — READY_FOR_HUMAN_STOP_GATE.** Phase 1 preflight **PASS**. **No runtime activation performed** — human approval phrase not received in this session. **10/10** governance-promoted packages validate. **6** non-thyroid activation candidates identified. **4** thyroid packages documented as runtime-deferred. **10** excluded packages confirmed untouched. Architecture gate **PASS**. Sprint closes as: **governance promotion complete / runtime activation deferred pending approval**.

---

## Phase 1 preflight findings

| # | Check | Result |
|---|-------|--------|
| 1 | 10 packages governance-promoted (BATCH2-PROMOTE-1) | **Yes** |
| 2 | 10 packages cleared (BATCH2-CLOSURE-1) | **Yes** |
| 3 | 10 excluded packages blocked | **Yes** |
| 4 | 4 thyroid packages runtime-deferred | **Yes** — no clinical sign-off in repo |
| 5 | 6 non-thyroid activation candidates | **Yes** |
| 6 | All 10 governance-promoted packages validate | **10/10 PASS** |
| 7 | Candidate activation keys unique | **Yes** |
| 8 | No active duplicate activation key | **Yes** — no collision with existing active frames |
| 9 | Activation mechanism identified | **Yes** (see below) |
| 10 | Files that would change on activation | Frame index + manifest metadata only |
| 11 | Rollback path defined | **Yes** — in execution register |
| 12 | No medical logic change required | **Confirmed** |

---

## STOP gate outcome

**Status:** `READY_FOR_HUMAN_STOP_GATE`

**Human approval received:** **No**

**Required approval phrase:** `APPROVE BATCH2 RUNTIME ACTIVATION`

**Activation performed:** **No**

---

## Runtime activation candidates (6)

| package_id |
|------------|
| pkg_kb47_creatine_kinase_high_exertional_muscle_injury |
| pkg_kb47_creatine_kinase_high_persistent_nonexertional_muscle_injury |
| pkg_kb47_eosinophil_pct_high_reactive_atopic_eosinophilia |
| pkg_kb47_eosinophil_pct_high_secondary_or_systemic_eosinophilia |
| pkg_kb47_eosinophils_abs_high_reactive_eosinophilic_inflammation |
| pkg_kb47_eosinophils_abs_high_hypereosinophilic_or_secondary_eosinophilia |

---

## Thyroid runtime-deferred (4)

| package_id | deferred_reason |
|------------|-----------------|
| pkg_kb47_free_t3_high_t3_predominant_thyrotoxicosis | thyroid_clinical_signoff_required_before_activation |
| pkg_kb47_free_t3_low_low_t3_syndrome | thyroid_clinical_signoff_required_before_activation |
| pkg_kb47_free_t4_high_thyrotoxicosis_context | thyroid_clinical_signoff_required_before_activation |
| pkg_kb47_free_t4_low_thyroid_hormone_deficiency | thyroid_clinical_signoff_required_before_activation |

---

## Excluded packages (10)

All androgen (8) + eGFR (2) — **confirmed untouched**, no file modifications.

---

## Activation mechanism (identified)

| Layer | Mechanism |
|-------|-----------|
| **Primary** | `medical_frame_identity_index_v1.yaml` — set `promotion_state: runtime_active_canonical`, `runtime_authority_status: active` for approved frames |
| **Secondary** | `package_manifest.yaml` — governance runtime activation metadata |
| **Loader** | `SignalRegistry` scans `knowledge_bus/packages/*/signal_library.yaml` (packages already on disk; no loader code change required) |
| **Code changes** | **None required** for governance-recorded activation |

**Proposed files on approval:** frame index (6 frames), 6 package manifests (metadata only), execution register update, optional `batch2_runtime_authority_v1.yaml`.

---

## Rollback path

No activation performed — rollback N/A for this sprint closure.

If Phase 3 activation is later approved and applied: revert frame index to `compiled_not_promoted` / `inactive` and remove manifest activation metadata for affected packages only.

---

## Packages activated / deferred

| Category | Count | Activated |
|----------|------:|-----------|
| Activation candidates | 6 | 0 (pending approval) |
| Thyroid deferred | 4 | 0 (by design) |
| Excluded | 10 | 0 |

---

## Validation output

**Package validators:** 10/10 PASS (`validate_knowledge_package.py` per package during preflight).

**Architecture gate:**

```text
architecture_validation_gate: PASS
validation_status: PASS (frame index)
validation_status: PASS (context modifier catalogue)
medical_intelligence_architecture_validation: PASS
```

---

## Runtime authority files changed

**None** — activation not performed.

---

## Carry-forward updates

| ID | Action |
|----|--------|
| CF-BATCH2-011 | Remains **Resolved** (BATCH2-PROMOTE-1) |
| CF-BATCH2-012 | **Open** — runtime activation deferred pending human approval |
| CF-BATCH2-013 | **Open (new)** — thyroid clinical sign-off before thyroid runtime activation |
| CF-BATCH2-007 | Remains Open |
| CF-BATCH2-010 | Remains Open |
| CF-CONTEXT-MOD-3 | Remains Open |

---

## Final Batch 2 cleared-promotion status

| Subset | Status |
|--------|--------|
| Governance promotion (10) | **Complete** |
| Runtime activation (6 candidates) | **Deferred pending STOP approval** |
| Thyroid (4) | **Deferred pending clinical sign-off** |
| Androgen + eGFR (10) | **Excluded** |

---

## Confirmations

- No runtime/frontend/evaluator **code** changes
- No medical logic changes
- No excluded package file changes
- No thyroid package file changes

---

## Next step

Human must reply with **`APPROVE BATCH2 RUNTIME ACTIVATION`** to authorize Phase 3 activation of the 6 non-thyroid candidates in a follow-up execution (same sprint continuation or re-run with approval recorded in execution register).
